- Method for preparing nilotinib monohydrochloride dihydrate crystal form A
-
The invention provides a method for preparing nilotinib monohydrochloride dihydrate crystal form A. Specifically, the method provided by the invention comprises the following steps: (1) mixing nilotinib a free alkali as shown in a formula I, hydrochloric
- -
-
Paragraph 0133-0162
(2021/08/07)
-
- CRYSTALLINE FORM OF NILOTINIB HYDROCHLORIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
-
The present invention relates to novel crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition comprising the same.
- -
-
Page/Page column 17-18
(2020/06/01)
-
- KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF
-
The present invention relates to kinase inhibitor C8-C16 aliphatic sulfate salts and compositions thereof.
- -
-
Page/Page column 91-92
(2020/01/08)
-
- PROCESS FOR THE PREPARATION OF PURE NILOTINIB AND ITS SALT
-
Object of the present invention is a process for the preparation of the pharmaceutical active ingredient Nilotinib free base or Nilotinib dihydrochloride dihydrate by means of an improved crystallization procedure.
- -
-
Paragraph 0139; 0140
(2018/12/04)
-
- NOVEL SALTS OF NILOTINIB AND CRYSTALLINE FORMS THEREOF
-
The present invention provides novel salts of Nilotinib and crystalline forms thereof. Specific salt and crystalline forms thereof provided by the present invention include Nilotinib trihydrochloride dihydrate Form APO-VIII, Nilotinib gentisate Form APO-I, Nilotinib gentisate Form APO-II, Nilotinib digentisate Form APO-III, Nilotinb dibenzoate Form APO-I, Nilotinib dilevulinate Form APO-I, Nilotinib saccharinate monohydrate Form APO-I, Nilotinib saccharinate Form APO-II, Nilotinib diglycolate Form APO-I and Nilotinib glycerophosphate Form APO-I.
- -
-
Paragraph 0042; 0091
(2018/05/24)
-
- Novel nilotinib hydrochloride crystal form and preparation method and medical application thereof
-
The invention relates to a novel nilotinib hydrochloride crystal form and a preparation method and medical application thereof, in particular to a novel nilotinib hydrochloride crystal form with the structural formula shown as the formula (I) (please see
- -
-
Paragraph 0037; 0038; 0039; 0040
(2017/08/28)
-
- NOVEL POLYMORPHIC FORM X OF NILOTINIB DIHYDROCHLORIDE HYDRATE
-
The present invention relates to a novel polymorph of nilotinib hydrochloride(Form X), to processes for its preparation, to pharmaceutical compositions containing the same and to its use in medicine.
- -
-
Page/Page column 11; 12
(2016/10/11)
-
- AN IMPROVED PROCESS FOR THE PREPARATION OF NILOTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
-
The present invention relates to an improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof, with high purity and yields.
- -
-
Page/Page column 16
(2015/06/25)
-
- SOLID FORMS OF NILOTINIB HYDROCHLORIDE
-
Disclosed are solid forms of Nilotinib hydrochloride and methods of preparation of various crystalline solvates of Nilotinib HCl including benzyl alcohol, acetic acid, propylene glycol, and isopropanol. Nilotinib HCl is a tyrosine kinase inhibitor used for the treatment of drug resistant chronic myelogenous leukemia (CML).
- -
-
Page/Page column 16; 17
(2014/05/07)
-
- PROCESS FOR THE PREPARATION OF NILOTINIB
-
The present invention relates a process for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, which process comprises converting a compound of formula (IV): or a pharmaceutically acceptable salt thereof, into the compound of formula (I) or a pharmaceutically acceptable salt thereof.
- -
-
-
- Process for the preparation of nilotinib hydrochloride
-
A process for the preparation of a hydrochloride salt of a compound of formula (I): which process comprises converting a compound of formula (IV): or a pharmaceutically acceptable salt thereof, into the hydrochloride salt of the compound of formula (I).
- -
-
-
- NILOTINIB SALTS AND CRYSTALLINE FORMS THEREOF
-
Nilotinib salts and crystalline forms thereof have been prepared and characterized.
- -
-
Page/Page column 51
(2012/01/14)
-
- NOVEL POLYMORPH OF NILOTINIB MONOHYDROCHLORIDE MONOHYDRATE
-
The present invention relates to a novel polymorph of 4-methyl-N-[3-(4-methyl-imidazol- 1-yl)-5-(trifluoromethyl)-phenyl]-3-[(4-pyridin-3-yl-pyrimidin-2-yl)amino] benzamide (nilotinib) monohydrochloride monohydrate, and to methods for preparing, pharmaceu
- -
-
Page/Page column 12-13
(2011/08/04)
-
- NILOTINIB DIHYDROCHLORIDE SALT
-
The present invention relates to nilotinib dihydrochloride and its hydrates, to methods for preparing nilotinib dihydrochloride and its hydrates, pharmaceutical compositions comprising nilotinib dihydrochloride and its hydrates, and methods of treatment u
- -
-
Page/Page column 13
(2011/04/19)
-
- Nilotinib intermediates and preparation thereof
-
Nilotinib?3HCl and its crystalline forms are described, and processes for the preparation of the same.
- -
-
Page/Page column 29
(2011/04/25)
-
- NILOTINIB INTERMEDIATES AND PREPARATION THEREOF
-
Intermediates of Nilotinib were prepared, including, for example, 3-(trifluoromethyl-5-(4-methyl-1H-imidazole-1-yl)-benzeneamine; 3-(4-(pyridin-3-yl)pyrimidin-2-ylamino) -4-methylbenzoyl halogen dihydrochloride; and N-(3-Bromo-5-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide. Nilotinib.3HCl and its crystalline forms are also described.
- -
-
Page/Page column 20
(2010/02/17)
-
- SALTS OF 4-METHYL-N-[3-(4-METHYL-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYL-PHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-BENZAMIDE
-
Salts of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes.
- -
-
Page/Page column 13-14
(2008/06/13)
-
- CRYSTALLINE FORMS OF 4-METHYL-N-[3-(4-METHYL-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYL-PHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-BENZAMIDE
-
Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared by various processes.
- -
-
Page/Page column 25
(2008/06/13)
-